Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,049 across all filing types
Latest filing 2021-10-05 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
News Verification
Regulatory Filings Classification · 100% confidence The document text is extremely short (78 characters) and contains no substantive content, financial data, or any report-related information. It only includes placeholders and an omitted picture note. There is no indication of any report, announcement, or filing type. Given the lack of content, the document cannot be classified as any specific report or announcement. According to the rules, such minimal or empty content defaults to Regulatory Filings (RNS) as a fallback category.
2021-10-05 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received marketing approval for a pharmaceutical product (Ryaltris) in multiple countries. It is addressed to stock exchanges and includes a request to take the announcement on record. The content focuses on product approval, regulatory status, and commercial plans, without any financial data, earnings, or management discussion. It is not a financial report, earnings release, or regulatory filing about financial performance. It is also not a report publication announcement or certification. The document is a corporate announcement related to marketing approval and product launch, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-09-30 English
Shareholders meeting
Regulatory Filings
2021-09-24 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received ANDA approval for a specific pharmaceutical product. It is addressed to stock exchanges and includes a media release. The content is an announcement of a regulatory approval event, not a financial report, management discussion, or any detailed financial data. The document length is 3797 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication of financial statements, earnings data, or detailed management commentary. Therefore, this document fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance-related disclosures that do not fit into other specific categories.
2021-09-21 English
Updates
Regulatory Filings Classification · 95% confidence The document text is extremely short (446 characters) and appears to be a formal letter or communication addressed to stock exchanges (BSE and NSE) referencing scrip codes and names. There is no substantive financial data, report content, or detailed information. It does not contain any financial statements, management discussion, or report details. Given the brevity and nature, it is likely a regulatory announcement or filing rather than a full report or detailed disclosure. It fits best as a Regulatory Filing (RNS) which is a fallback category for miscellaneous filings that do not fit other specific categories.
2021-09-15 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the conclusion of a post marketing surveillance (PMS) study on the drug Favipiravir (FabiFlu®) by Glenmark Pharmaceuticals. It provides a summary of the study's findings regarding safety and efficacy in COVID-19 patients. The document is addressed to stock exchanges and requests the announcement to be taken on record. It does not contain detailed financial data, regulatory certifications, or comprehensive financial reports. It is not an earnings release, annual report, or interim report. It is a corporate announcement about a clinical study result, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other specific categories such as earnings, management changes, or capital updates. The document length is 6280 characters, which is moderate, and the content is a media release rather than a full report or presentation. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-09-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.